NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Price Target & Analyst Ratings

$26.98

+0.39 (+1.47%)

(As of 09/29/2023 ET)

Compare

Today's Range: $26.44
▼
$27.19
50-Day Range: $21.07
▼
$29.77
52-Week Range: $13.29
▼
$30.25

Volume: 502,240 shs
Average Volume: 507,016 shs
Market Capitalization: $1.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.08

IDEAYA Biosciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$32.08
18.89% Upside

High Prediction	$43.00
Average Prediction	$32.08
Low Prediction	$24.00

Type	Current 9/30/22 to 9/30/23	1 Month Ago 8/31/22 to 8/31/23	3 Months Ago 7/2/22 to 7/2/23	1 Year Ago 9/30/21 to 9/30/22
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.08	$31.46	$29.40	$27.50
Predicted Upside	18.89% Upside	55.16% Upside	73.16% Upside	132.64% Upside

Get IDEAYA Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

IDYA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IDYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IDEAYA Biosciences Stock vs. The Competition

Type	IDEAYA Biosciences	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.66	2.49
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	18.89% Upside	867.99% Upside	698.21% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/12/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$31.00 ➝ $37.00	+25.08%
9/12/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$40.00 ➝ $43.00	+45.37%
8/17/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$28.00 ➝ $32.00	+28.26%
8/11/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$30.00 ➝ $32.00	+26.53%
8/11/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$30.00 ➝ $35.00	+37.25%
8/8/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/8/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$33.00	+53.27%
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$33.00	+53.27%
4/24/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $40.00	+111.98%
4/24/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$18.00 ➝ $24.00	+60.75%
3/23/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$26.00	+87.59%
3/17/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$26.00 ➝ $29.00	+93.46%
12/28/2022	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Z. Jallah Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$29.00	+75.44%
11/18/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$18.00 ➝ $24.00	+32.09%

(Data available from 9/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

IDYA Price Target - Frequently Asked Questions

What is IDEAYA Biosciences's consensus rating and price target?: According to the issued ratings of 14 analysts in the last year, the consensus rating for IDEAYA Biosciences stock is Buy based on the current 14 buy ratings for IDYA. The average twelve-month price prediction for IDEAYA Biosciences is $32.08 with a high price target of $43.00 and a low price target of $24.00. Learn more on IDYA's analyst rating history.
Do Wall Street analysts like IDEAYA Biosciences more than its competitors?: Analysts like IDEAYA Biosciences more than other Medical companies. The consensus rating for IDEAYA Biosciences is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how IDYA compares to other companies.
Does IDEAYA Biosciences's stock price have much upside?: According to analysts, IDEAYA Biosciences's stock has a predicted upside of 51.37% based on their 12-month price targets.

What analysts cover IDEAYA Biosciences?: IDEAYA Biosciences has been rated by JPMorgan Chase & Co., Leerink Partnrs, Oppenheimer, Royal Bank of Canada, SVB Leerink, SVB Securities, The Goldman Sachs Group, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:IDYA) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial